VREOF Vireo Growth Inc.

OTC Pharmaceutical Preparations A1 CIK: 0001771706
AI RATING
SELL
72% Confidence

Investment Thesis

Vireo Growth demonstrates exceptional revenue growth of 170.4% YoY, reaching $268.8M, but remains deeply unprofitable with a -25.3% net margin and -$68.1M net loss. Despite adequate liquidity and low leverage, the company's negative free cash flow of -$24.6M indicates structural cash burn that threatens sustainability without an imminent path to profitability.

Strengths

  • + Exceptional revenue growth of 170.4% YoY demonstrates strong market demand
  • + Healthy gross margin of 47.3% indicates viable core product economics
  • + Strong balance sheet with low debt-to-equity ratio of 0.19x and $102.2M cash reserves

Risks

  • ! Massive net losses of -$68.1M with -25.3% net margin despite revenue scale
  • ! Negative free cash flow of -$24.6M driven by high capital expenditure burn
  • ! Inability to achieve profitability at $268.8M revenue scale suggests structural business model challenges
  • ! Zero insider Form 4 filings in past 90 days indicates lack of management conviction

Key Metrics to Watch

Financial Metrics

Revenue
268.8M
Net Income
-68.1M
EPS (Diluted)
$-0.09
Free Cash Flow
-24.6M
Total Assets
817.2M
Cash
102.2M

Profitability Ratios

Gross Margin 47.3%
Operating Margin -0.4%
Net Margin -25.3%
ROE -22.2%
ROA -8.3%
FCF Margin -9.2%

Balance Sheet & Liquidity

Current Ratio
1.59x
Quick Ratio
1.28x
Debt/Equity
0.19x
Debt/Assets
62.4%
Interest Coverage
-0.12x
Long-term Debt
58.2M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings. It does not include stock price data and should not be considered financial advice. All fundamental data is sourced from SEC public domain filings. Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR | Analysis Date: 2026-04-18T20:12:22.386070 | Data as of: 2025-12-31 | Powered by Claude AI